<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04074421</url>
  </required_header>
  <id_info>
    <org_study_id>(2019) Study No. 413</org_study_id>
    <nct_id>NCT04074421</nct_id>
  </id_info>
  <brief_title>Effects of Continuous Treatment With Rifaximin and Probiotics on the Gut Microbiota of Patients With IBS-D</brief_title>
  <official_title>Effects of Continuous Treatment With Rifaximin and Probiotics on the Gut Microbiota of Patients With Diarrhoea-predominant Irritable Bowel syndrome-a Multicentre Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sir Run Run Shaw Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Zhejiang Chinese Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Central Hospital of Lishui City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will use the latest Rome IV criteria to recruit IBS-D patients and evaluate the effects of
      repeated treatment with rifaximin and sequential treatment with rifaximin and probiotics on
      different symptoms and quality of life. High-throughput sequencing combined with real-time
      quantitative PCR will be used to comprehensively analyze the effects of different drugs on
      intestinal flora. The study has important guiding significance for the treatment of patients
      with IBS-D.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to the Rome IV diagnostic criteria, 200 patients with with diarrhoea-predominant
      irritable bowel syndrome (IBS-D) from the multi-center (8 units in the country) will be
      enrolled. The IBS Severity Inventory (IBS-SSS) and IBS Quality of Life Scores (QOL) will be
      used to evaluate the effect of treatments. Retreatment patients who are initially treated and
      not satisfied with the improvement of symptoms and quality of life will be treated with
      Rifaximin for 2 weeks. Fecal specimens will be collected from patients who responded to
      treatment, and the fecal bacteria will be analyzed by real-time polymerase chain reaction
      (PCR) using 16 S ribosomal ribonucleic acid (rRNA) gene. Patients who responded to Rifaximin
      treatment will be randomized into A (Probiotics group) and B (Placebo group). IBS symptom
      grade score and quality of life score will be evaluated before and after treatment, and fecal
      specimens of the responding patients will be collected for intestinal probiotics and harmful
      bacteria detection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the IBS symptom grade score</measure>
    <time_frame>baseline</time_frame>
    <description>The IBS Severity Inventory (IBS-SSS) will be used to evaluate the IBS symptom grade score The IBS Severity Inventory (IBS-SSS) will be used to evaluate the IBS symptom grade score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the quality of life score</measure>
    <time_frame>baseline</time_frame>
    <description>IBS Quality of Life Scores (QOL) will be used to evaluate the quality of life score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the IBS symptom grade score</measure>
    <time_frame>2 weeks</time_frame>
    <description>The IBS Severity Inventory (IBS-SSS) will be used to evaluate the IBS symptom grade score The IBS Severity Inventory (IBS-SSS) will be used to evaluate the IBS symptom grade score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the quality of life score</measure>
    <time_frame>2 weeks</time_frame>
    <description>IBS Quality of Life Scores (QOL) will be used to evaluate the quality of life score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the IBS symptom grade score</measure>
    <time_frame>12 weeks</time_frame>
    <description>The IBS Severity Inventory (IBS-SSS) will be used to evaluate the IBS symptom grade score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the quality of life score</measure>
    <time_frame>12 weeks</time_frame>
    <description>IBS Quality of Life Scores (QOL) will be used to evaluate the quality of life score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>16 S rRNA (ribosomal ribonucleic acid) to detect gut microbiota</measure>
    <time_frame>12 weeks</time_frame>
    <description>16 S rRNA (ribosomal ribonucleic acid) sequencing will be applied to determine the change of microbial community</description>
  </primary_outcome>
  <primary_outcome>
    <measure>16 S rRNA (ribosomal ribonucleic acid) to detect gut microbiota</measure>
    <time_frame>baseline</time_frame>
    <description>16 S rRNA (ribosomal ribonucleic acid) sequencing will be applied to determine the change of microbial community</description>
  </primary_outcome>
  <primary_outcome>
    <measure>16 S rRNA (ribosomal ribonucleic acid) to detect gut microbiota</measure>
    <time_frame>2 weeks</time_frame>
    <description>16 S rRNA (ribosomal ribonucleic acid) sequencing will be applied to determine the change of microbial community</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>IBS - Irritable Bowel Syndrome</condition>
  <condition>Gut Microbiota</condition>
  <arm_group>
    <arm_group_label>Rifaximin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Repeating treatment of Rifaximin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotics group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sequential treatment of probiotics called Bacillus subtilis and Enterococcus faecium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>A non-aminoglycoside intestinal antibiotic, 400mg, twice one day for 2 weeks.</description>
    <arm_group_label>Rifaximin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probiotic Formula</intervention_name>
    <description>A probiotic called Enterococcus faecium, 500mg, triple one day for 4 weeks.</description>
    <arm_group_label>Probiotics group</arm_group_label>
    <other_name>probiotic formula Bacillus subtilis and Enterococcus faecium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo oral tablet that has no therapeutic effect</description>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-75 years old;

          -  in line with the diagnostic criteria of diarrhea-type irritable bowel syndrome Roman
             IVï¼›

          -  blood routine, blood biochemistry, stool examination and colonoscopy within 2 years
             are no problem;

          -  no intestinal warning symptoms

        Exclusion Criteria:

          -  suffering from severe heart, lung, liver, kidney, nervous system diseases;

          -  suffering from mental disorders caused by schizophrenia, brain organic and physical
             diseases;

          -  suffering from other diseases that may affect intestinal function (such as diabetes,
             thyroid disease);

          -  History of previous abdominal surgery (excluding history of cholecystectomy or
             appendectomy);

          -  pregnant or lactating women;

          -  have undergone colonoscopy in the past month or accept other bowel preparation
             operations;

          -  In the past 1 month, have used antibiotics, antidiarrheal agents, intestinal flora
             regulation, Chinese medicine and other drugs;

          -  have participated in other dietary treatments;

          -  understand communication barriers, unable to communicate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liangjing Wang, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liangjing Wang, Ph.D</last_name>
    <phone>+8613777848083</phone>
    <email>wangljzju@zju.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhenghua Lin, Ph.D</last_name>
    <phone>+8618858152082</phone>
    <email>floretwan@zju.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Second Affiliated Hospital, School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian-an The President</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 26, 2019</study_first_submitted>
  <study_first_submitted_qc>August 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2019</study_first_posted>
  <last_update_submitted>July 26, 2020</last_update_submitted>
  <last_update_submitted_qc>July 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rifaximin</keyword>
  <keyword>Probiotics</keyword>
  <keyword>IBS-D</keyword>
  <keyword>gut microbiota</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The study is not yet recruiting and unfinished.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

